Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study-Reference-Cited by-同舟云学术

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study

Published:2014-02-10 Issue:9 Volume:20 Page:1265-1268
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Frisullo Giovanni¹,Calabrese Massimiliano²,Tortorella Carla³,Paolicelli Damiano³,Ragonese Paolo⁴,Annovazzi Pietro⁵,Radaelli Marta⁶,Malucchi Simona⁷,Gallo Antonio⁸,Tomassini Valentina⁹,Nociti Viviana¹¹⁰,D’Onghia Mariangela³,Lo Re Vincenzina⁴,Rodegher Mariemma⁶,Solaro Claudio¹¹,Gasperini Claudio¹²

Affiliation:

1. Department of Neurosciences, Catholic University of Rome, Italy

2. Department of Neurological and Movement Sciences, University of Verona, Italy

3. Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy

4. Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Italy

5. Centro Studi SM, AO Sant’Antonio Abate - Gallarate (VA), Italy

6. Department of Neurology, San Raffaele Hospital, Milan, Italy

7. Centro di Riferimento Regionale per la Sclerosi Multipla-Neurologia 2, A.O.U. San Luigi Gonzaga, Orbassano, Italy

8. Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Naples, Italy

9. Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, University Hospital of Wales, Cardiff University, UK

10. Don Carlo Gnocchi Foundation, Rome, Italy

11. Neurology Unit - Azienda Sanitaria Locale 3, Genovese, Genoa, Italy

12. San Camillo Forlanini Hospital, Rome, Italy

Abstract

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing–remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458514521311

Reference10 articles.

1. Multiple sclerosis and other immunologic diseases

2. Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort

3. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease

4. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis

5. Long-Term Follow-Up of 106 Multiple Sclerosis Patients Undergoing Interferon-β 1a or 1b Therapy: Predictive Factors of Thyroid Disease Development and Duration

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis: time for early treatment with high-efficacy drugs;Journal of Neurology;2023-10-18

2. Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis;CNS Drugs;2023-09-07

3. Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea;Endocrinology and Metabolism;2023-08-31

4. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS);Current Reviews in Clinical and Experimental Pharmacology;2023-03

5. A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors;Endocrine;2023-01-03